Is Pegasys Still Used for Chronic Hepatitis C?
Pegasys (peginterferon alfa-2a) is rarely used today for chronic hepatitis C (HCV) treatment. Modern direct-acting antivirals (DAAs) like sofosbuvir, glecaprevir/pibrentasvir, and others cure over 95% of cases in 8-12 weeks with fewer side effects, making interferon-based regimens like Pegasys obsolete for most patients.[1][2]
Guidelines from the American Association for the Study of Liver Diseases (AASLD) and European Association for the Study of the Liver (EASL) recommend DAAs as first-line therapy since 2014-2016, reserving Pegasys for rare cases like decompensated cirrhosis or post-transplant recurrence where DAAs fail or are unavailable.[3]
Why Was Pegasys Phased Out?
Pegasys, approved in 2002, was combined with ribavirin for HCV genotypes 1-6, achieving 40-50% sustained virologic response (SVR) rates. It required weekly injections for 24-48 weeks and caused flu-like symptoms, depression, and anemia in up to 20% of patients. DAAs outperform it with pan-genotypic efficacy, oral dosing, and minimal toxicity.[1][4]
When Might Doctors Still Prescribe It?
Limited use persists in:
- Resource-limited settings without DAA access (e.g., parts of Africa, Asia).
- Clinical trials or compassionate use for DAA-resistant strains.
- Coinfections like HCV-HIV where specific DAAs aren't tolerated.
Global HCV treatment data shows interferon use dropped below 5% by 2020.[2]
What Are the Current Standard Treatments?
| Treatment Example | Duration | SVR Rate | Common Use |
|-------------------|----------|----------|-------------|
| Epclusa (sofosbuvir/velpatasvir) | 12 weeks | >98% | All genotypes |
| Mavyret (glecaprevir/pibrentasvir) | 8 weeks | >98% | Most patients, no cirrhosis |
| Vosevi (sofosbuvir/velpatasvir/voxilaprevir) | 12 weeks | 95-100% | DAA failures |
These are covered by most insurance and WHO essential medicines lists.[3][5]
Availability and Patent Status
Pegasys remains available generically in some markets, with U.S. patent expiry in 2019. No major shortages reported, but demand is negligible.6
[1]: AASLD-IDSA HCV Guidance (aasldpubs.onlinelibrary.wiley.com)
[2]: WHO Hepatitis C Guidelines (who.int)
[3]: EASL HCV Recommendations (easl.eu)
[4]: FDA Pegasys Label (fda.gov)
[5]: Drugs.com HCV Treatment Comparisons (drugs.com)